These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 7737902)

  • 1. Pharmacological correlation between total drug concentration and lactones of CPT-11 and SN-38 in patients treated with CPT-11.
    Sasaki Y; Yoshida Y; Sudoh K; Hakusui H; Fujii H; Ohtsu T; Wakita H; Igarashi T; Itoh K
    Jpn J Cancer Res; 1995 Jan; 86(1):111-6. PubMed ID: 7737902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A limited sampling model for estimating pharmacokinetics of CPT-11 and its metabolite SN-38.
    Sasaki Y; Mizuno S; Fujii H; Ohtsu T; Wakita H; Igarashi T; Itoh K; Sekine I; Miyata Y; Saijo N
    Jpn J Cancer Res; 1995 Jan; 86(1):117-23. PubMed ID: 7737903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kinetics of the in vivo interconversion of the carboxylate and lactone forms of irinotecan (CPT-11) and of its metabolite SN-38 in patients.
    Rivory LP; Chatelut E; Canal P; Mathieu-Boué A; Robert J
    Cancer Res; 1994 Dec; 54(24):6330-3. PubMed ID: 7987823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of CPT-11 in rhesus monkeys.
    Inaba M; Ohnishi Y; Ishii H; Tanioka Y; Yoshida Y; Sudoh K; Hakusui H; Mizuno N; Ito K; Sugiyama Y
    Cancer Chemother Pharmacol; 1998; 41(2):103-8. PubMed ID: 9443622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks.
    Rowinsky EK; Grochow LB; Ettinger DS; Sartorius SE; Lubejko BG; Chen TL; Rock MK; Donehower RC
    Cancer Res; 1994 Jan; 54(2):427-36. PubMed ID: 8275479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical pharmacokinetics of irinotecan and its metabolites: a population analysis.
    Xie R; Mathijssen RH; Sparreboom A; Verweij J; Karlsson MO
    J Clin Oncol; 2002 Aug; 20(15):3293-301. PubMed ID: 12149304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in phase I/II trials.
    Rivory LP; Haaz MC; Canal P; Lokiec F; Armand JP; Robert J
    Clin Cancer Res; 1997 Aug; 3(8):1261-6. PubMed ID: 9815808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pharmacokinetic and pharmacodynamic analysis of CPT-11 and its active metabolite SN-38.
    Sasaki Y; Hakusui H; Mizuno S; Morita M; Miya T; Eguchi K; Shinkai T; Tamura T; Ohe Y; Saijo N
    Jpn J Cancer Res; 1995 Jan; 86(1):101-10. PubMed ID: 7737901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Limited sampling models for simultaneous estimation of the pharmacokinetics of irinotecan and its active metabolite SN-38.
    Chabot GG
    Cancer Chemother Pharmacol; 1995; 36(6):463-72. PubMed ID: 7554037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma pharmacokinetics of 7-ethyl-10-hydroxycamptothecin (SN-38) after intravenous administration of SN-38 and irinotecan (CPT-11) to rats.
    Kaneda N; Hosokawa Y; Yokokura T; Awazu S
    Biol Pharm Bull; 1997 Sep; 20(9):992-6. PubMed ID: 9331983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials.
    Chabot GG; Abigerges D; Catimel G; Culine S; de Forni M; Extra JM; Mahjoubi M; Hérait P; Armand JP; Bugat R
    Ann Oncol; 1995 Feb; 6(2):141-51. PubMed ID: 7786822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-performance liquid chromatographic quantitation of total and lactone 20(S)camptothecin in patients receiving oral 20(S)camptothecin.
    Ahmed F; Vyas V; Saleem A; Li XG; Zamek R; Cornfield A; Haluska P; Ibrahim N; Rubin EH; Gupta E
    J Chromatogr B Biomed Sci Appl; 1998 Apr; 707(1-2):227-33. PubMed ID: 9613954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma and cerebrospinal fluid pharmacokinetics of 9-aminocamptothecin (9-AC), irinotecan (CPT-11), and SN-38 in nonhuman primates.
    Blaney SM; Takimoto C; Murry DJ; Kuttesch N; McCully C; Cole DE; Godwin K; Balis FM
    Cancer Chemother Pharmacol; 1998; 41(6):464-8. PubMed ID: 9554590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical pharmacokinetics of irinotecan.
    Chabot GG
    Clin Pharmacokinet; 1997 Oct; 33(4):245-59. PubMed ID: 9342501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic characteristics of the novel anticancer agent CPT-11 and its active metabolite in plasma and lung lymph fluid following intravenous administration to sheep.
    Koizumi T; Kubo K; Hanaoka M; Miyahara T; Kaneki T; Yamamoto H; Ge RL; Fujimoto K; Kobayashi T; Sekiguchi M
    Arzneimittelforschung; 1998 Nov; 48(11):1097-100. PubMed ID: 9850432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simultaneous determination of the lactone and carboxylate forms of irinotecan (CPT-11) and its active metabolite SN-38 by high-performance liquid chromatography: application to plasma pharmacokinetic studies in the rat.
    Yang X; Hu Z; Chan SY; Goh BC; Duan W; Chan E; Zhou S
    J Chromatogr B Analyt Technol Biomed Life Sci; 2005 Jul; 821(2):221-8. PubMed ID: 15936253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Salivary drug monitoring of irinotecan and its active metabolite in cancer patients.
    Takahashi T; Fujiwara Y; Sumiyoshi H; Isobe T; Yamaoka N; Yamakido M
    Cancer Chemother Pharmacol; 1997; 40(5):449-52. PubMed ID: 9272124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determination of irinotecan and its metabolite SN-38 in rabbit plasma and tumors using a validated method of tandem mass spectrometry coupled with liquid chromatography.
    Park DJ; Won JH; Cho AR; Yun HJ; Heo JH; Hwhang TH; Lee DH; Kim WM
    J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Jul; 962():147-152. PubMed ID: 24927278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversed-phase high-performance liquid chromatographic method for the simultaneous quantitation of the carboxylate and lactone forms of the camptothecin derivative irinotecan, CPT-11, and its metabolite SN-38 in plasma.
    Rivory LP; Robert J
    J Chromatogr B Biomed Appl; 1994 Nov; 661(1):133-41. PubMed ID: 7866541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification and kinetics of a beta-glucuronide metabolite of SN-38 in human plasma after administration of the camptothecin derivative irinotecan.
    Rivory LP; Robert J
    Cancer Chemother Pharmacol; 1995; 36(2):176-9. PubMed ID: 7767955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.